By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...
The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...
Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Pharmaceutical Technology on MSN2d
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKAbrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
COVID, flu and RSV levels have already hit their peaks. (Pollen levels and springtime allergies are a whole different story.) ...
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
More than 190,000 people still sought medical help for acute respiratory infection (ARI), including 30,000 with ...
From giant sea spiders to "sea pigs" and "sea butterflies" — analysing the rich biodiversity in Antarctica has thrilled ...
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
In primary care settings, the burden of RSV on young children and their guardians often varied between the countries of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback